Nelonemdaz: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{Short description|A | {{Short description|A pharmaceutical drug used in anesthesia}} | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = | | verifiedrevid = 477002123 | ||
| IUPAC_name = (2S)-2-[[ | | IUPAC_name = (2S)-2-[(2S)-2-[[2-(2,6-dimethylanilino)acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid | ||
| image = Nelonemdaz.svg | | image = Nelonemdaz.svg | ||
| | | image_size = 200px | ||
| | | image_alt = Chemical structure of Nelonemdaz | ||
}} | }} | ||
'''Nelonemdaz''' is a | '''Nelonemdaz''' is a pharmaceutical compound that has been investigated for its potential use in [[anesthesia]] and [[neuroprotection]]. It is a novel drug that combines the properties of an [[NMDA receptor antagonist]] and a [[serotonin receptor]] modulator, aiming to provide both anesthetic and neuroprotective effects. | ||
==Pharmacology== | |||
Nelonemdaz acts primarily as an antagonist of the [[N-methyl-D-aspartate receptor|NMDA receptor]], which is a subtype of [[glutamate receptor]]s in the brain. By inhibiting these receptors, Nelonemdaz can reduce excitotoxicity, a process that can lead to [[neuronal damage]] and is implicated in various [[neurological disorders]]. Additionally, Nelonemdaz modulates [[serotonin receptors]], which may contribute to its neuroprotective properties. | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Nelonemdaz is designed to | The dual action of Nelonemdaz on NMDA and serotonin receptors is designed to provide a synergistic effect. The NMDA receptor antagonism helps in reducing excessive [[glutamate]] activity, which is often associated with [[ischemic brain injury]] and other forms of [[neurodegeneration]]. The modulation of serotonin receptors may help in stabilizing mood and providing additional neuroprotection, although the exact mechanisms are still under investigation. | ||
== | ==Clinical Applications== | ||
Nelonemdaz has been primarily studied in the context of [[stroke]] and [[traumatic brain injury]]. Its ability to mitigate excitotoxicity makes it a promising candidate for reducing brain damage following these events. However, as of the latest updates, Nelonemdaz is still undergoing clinical trials to establish its efficacy and safety profile. | |||
== | ==Development and Research== | ||
Research on Nelonemdaz is ongoing, with several studies focusing on its pharmacokinetics, optimal dosing strategies, and potential side effects. The drug's development is part of a broader effort to find effective treatments for acute neurological conditions where rapid intervention can significantly improve outcomes. | |||
==Related | ==Related pages== | ||
* [[ | * [[Anesthesia]] | ||
* [[Neuroprotection]] | * [[Neuroprotection]] | ||
* [[ | * [[NMDA receptor antagonist]] | ||
* [[Serotonin receptor]] | |||
* [[Stroke]] | |||
* [[Traumatic brain injury]] | |||
[[Category:Anesthetics]] | |||
[[Category:Neuroprotective agents]] | [[Category:Neuroprotective agents]] | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
Latest revision as of 05:03, 6 March 2025
A pharmaceutical drug used in anesthesia
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (2S)-2-[(2S)-2-[[2-(2,6-dimethylanilino)acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
| image = Nelonemdaz.svg
| image_size = 200px
| image_alt = Chemical structure of Nelonemdaz
}}
Nelonemdaz is a pharmaceutical compound that has been investigated for its potential use in anesthesia and neuroprotection. It is a novel drug that combines the properties of an NMDA receptor antagonist and a serotonin receptor modulator, aiming to provide both anesthetic and neuroprotective effects.
Pharmacology[edit]
Nelonemdaz acts primarily as an antagonist of the NMDA receptor, which is a subtype of glutamate receptors in the brain. By inhibiting these receptors, Nelonemdaz can reduce excitotoxicity, a process that can lead to neuronal damage and is implicated in various neurological disorders. Additionally, Nelonemdaz modulates serotonin receptors, which may contribute to its neuroprotective properties.
Mechanism of Action[edit]
The dual action of Nelonemdaz on NMDA and serotonin receptors is designed to provide a synergistic effect. The NMDA receptor antagonism helps in reducing excessive glutamate activity, which is often associated with ischemic brain injury and other forms of neurodegeneration. The modulation of serotonin receptors may help in stabilizing mood and providing additional neuroprotection, although the exact mechanisms are still under investigation.
Clinical Applications[edit]
Nelonemdaz has been primarily studied in the context of stroke and traumatic brain injury. Its ability to mitigate excitotoxicity makes it a promising candidate for reducing brain damage following these events. However, as of the latest updates, Nelonemdaz is still undergoing clinical trials to establish its efficacy and safety profile.
Development and Research[edit]
Research on Nelonemdaz is ongoing, with several studies focusing on its pharmacokinetics, optimal dosing strategies, and potential side effects. The drug's development is part of a broader effort to find effective treatments for acute neurological conditions where rapid intervention can significantly improve outcomes.
